AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02850952 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehab MATRIX
Description: Rehab MATRIX is a patient assignment tool that objectively categorizes patients undergoing inpatient rehabilitation based on nurse identified acuity variables.
Study NCT03941483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1128
Description: Intravenous Infusion
Study NCT03941483 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous Infusion
Study NCT02114177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simeprevir
Description: 150 participants will receive 1 capsule of 150 mg simeprevir orally once daily for 12 weeks in Arm 1.
Study NCT01313208 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etanercept
Description: Administered by subcutaneous injection once weekly.
Study NCT01313208 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: etanercept
Description: Administered by subcutaneous injection once weekly.
Study NCT01313208 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo subcutaneous injection
Study NCT01313208 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DMARD Therapy
Description: Standard-of-care DMARD therapy, including methotrexate, sulfasalazine, leflunomide, minocycline, and/or hydroxychloroquine
Study NCT01313208 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: DMARD Therapy
Description: Standard-of-care DMARD therapy, including methotrexate, sulfasalazine, leflunomide, minocycline, and/or hydroxychloroquine
Study NCT04518982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab and lenalidomide
Description: Drug: Sintilimab 200mg ivgtt on day 1. Drug: lenalidomide 10mg orally once a day, day 1-14.
Study NCT04518982 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sintilimab placebo and lenalidomide placebo
Description: Drug: Sintilimab placebo ivgtt on day 1. Drug: lenalidomide placebo orally once a day, day 1-14.
Study NCT01383967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2979165
Description: Administered orally
Study NCT01647646 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Seretide
Description: Using Symbicort and Seretide for asthma control measurements Compared with efficacy and safety
Study NCT01131611 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBPT
Description: Cognitive-Behavioral Based Physical Therapy
Study NCT01131611 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control-Attention
Description: Standard of Care + weekly phone calls
Study NCT01383967 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Administered orally
Study NCT00593840 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity modulated radiation therapy
Study NCT02596152 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mini-trampoline
Description: Intervention period lasts 12 weeks, training is group instructed, twice weekly. Training sessions are one hour each. The training intensity of the two interventional arms is comparable. The training progression is defined in advance.
Study NCT02114177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simeprevir
Description: 150 participants will receive 1 capsule of 150 mg simeprevir orally once daily for 8 weeks in Arm 2
Study NCT02114177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Description: 150 participants will receive 1 tablet of 400 mg sofosbuvir orally once daily for 12 weeks in Arm 1.
Study NCT02114177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Description: 150 participants will receive 1 tablet of 400 mg sofosbuvir orally once daily for 8 weeks in Arm 2.
Study NCT03929003 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Inspired
Description: The investigators will be studying the ability of using videogame-based rewards to increase smoking abstinence when they are made contingent on meeting abstinence goals.
Study NCT03929003 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Inspired
Description: The investigators will be studying the ability of using videogame-based rewards to increase smoking abstinence when they are made contingent on meeting abstinence goals.
Study NCT03714438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medicago Sativa
Description: Single oral doses of Medicago sativa (1,500 mg), 30 min before before the oral glucose tolerance test.
Study NCT03714438 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single oral doses of placebo (1,500 mg), 30 min before before the oral glucose tolerance test.
Study NCT02088125 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Breath Stacking
Description: Breath Stacking A mask was used with two one-way valves (inspiratory limb and expiratory limb), which was coupled to the patient's face allowing only inspiration, while the expiratory branch remained occluded for the individual only perform successive inspiratory efforts.
Study NCT02088125 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Incentive Spirometry
Description: The Incentive Spirometry was characterized by the use of the incentive spirometer volume, in which volunteer used a nasal clip and was instructed to inhale slowly and deeply through the mouthpiece of the equipment from functional residual capacity to total lung capacity.
Study NCT01464749 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Task-oriented circuit class training
Description: 5 sessions/week over 2 weeks (10 sessions) 120 minutes/each
Study NCT01464749 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: usual care
Description: no specific rehabilitation
Study NCT01850953 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: This is an approved smoking cessation medication.
Study NCT01850953 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03919565 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir Disoproxil Fumarate
Description: Patients would receive oral Tenofovir Disoproxil Fumarate 300mg once per day.
Study NCT03919565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon Alfa-2a
Description: Patients would receive subcutaneous injection of Peginterferon Alfa-2a 180 μg once per week.
Study NCT03919565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon Alfa-2b
Description: Patients would receive subcutaneous injection of Peginterferon Alfa-2b 80 μg once per week.
Study NCT01790607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-2745 /CNS 7056
Study NCT03199677 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib is an oral tyrosine kinase inhibitor.
Study NCT03368781 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AcQMap Imaging and Mapping System
Description: 3D Cardiac Imaging and Mapping during ablation procedures
Study NCT02560220 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mitomycin C-induced peripheral blood mononuclear cells (MICs)
Description: MICs are given intravenously 2 or 7 days before kidney transplantation from a living donor
Study NCT03273686 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Discharge the NG tube during the surgery
Description: Discharge the NG tube during the surgery.
Study NCT02596152 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nordic Walking
Description: Intervention period lasts 12 weeks, training is group instructed, twice weekly. Training sessions are one hour each. The training intensity of the two interventional arms is comparable. The training progression is defined in advance.
Study NCT00889681 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arctic Front Cardiac Cryoablation System
Description: The CryoCath Arctic Front® Cardiac CryoAblation Catheter System, including the Freezor MAX Cardiac Cryoablation Catheter, is indicated for the treatment of patients with paroxysmal atrial fibrillation to reduce the likelihood of subsequent detectable atrial fibrillation.
Study NCT03054714 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: catheter replacement
Description: catheter removal and delayed replacement, versus exchange over a guidewire
Study NCT03249402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethinyl Estradiol + Levonorgestrel
Description: Participants will receive one OC tablet containing EE 0.03 mg and LN 0.15 mg once daily on Days 1 to 21 in cycles 1 and 2.
Study NCT03249402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42847922
Description: Participants will receive 40 mg of JNJ-42847922 once daily on Days 14 to 21 in cycle 2.
Study NCT00692887 — intervention group
Intervention type: DEVICE
Intervention: PHP - Preferential Hyperacuity Perimeter (Foresee)
Description: computerized test
Study NCT04016857 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RIPC
Description: 4 cycles of 5-min inflation to 200 mmHg followed by 5-min deflation of arm cuff
Study NCT04016857 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Control
Description: deflated cuff placed on the left arm for 40 min
Study NCT03717363 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Training programme
Description: Training program in the primary care center supervised by a physiotherapist. The duration is two months and the frequency of sessions 3 times / week. Each session lasts 60 minutes.(30 minutes of aerobic exercise and 15 minutes of strength exercise).
Study NCT01058239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given intravenously on days 1, 4, 8 and 11 of every cycle
Study NCT01058239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: given intravenously on days 1, 8 and 15 of Cycle 1 and on Day 1 of subsequent cycles
Study NCT03557125 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: QL Block
Description: If the subject has been randomized to the block group, a subcutaneous lidocaine skin wheel placed will be placed followed by a quadratus lumborum regional block with 40 ml, 0.25% ropivacaine deposited deep to the transversus abdominus apnoneurosis and superficial to the fascia transversalis with direct ultrasound guidance. Local anesthetic will be injected in 5 ml aliquots with aspiration for blood performed before and after the injection of each aliquot. Local anesthetic injection will also be observed with real time ultrasound guidance.
Study NCT03557125 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline Skin Wheel
Description: The skin will be cleaned with chlorhexidine. If the subject has been randomized to the no block group, a subcutaneous saline skin wheel will be placed and the procedure would end at this point.
Study NCT03733938 — intervention group
Intervention type: OTHER
Intervention: endodontic microsurgery
Description: teeth with failed root canal treatment will be treated by endodontic microsurgery
Study NCT01964183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tolterodine
Description: Oral
Study NCT01964183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mirabegron
Description: Oral
Study NCT05086848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan liposome、5-fluorouracil、Leucovorin
Description: Irinotecan liposome、5-fluorouracil、Leucovorin
Study NCT01546883 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate (Pradaxa)
Description: 150mg bid or 75mg bid for a period of one year
Study NCT00746083 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Challenge!
Description: Each adolescent in the intervention group received 12 lessons administered in adolescent's home or community by a personal trainer (a college-aged mentor). The lessons focused on behavior change relating to diet and physical activity and was based on social cognitive theory. At the end of each lesson the adolescent set a behavior change goal for themselves. The adolescents were taught how to track their goals and they discussed thir ability/inability to meet their goals at each meeting with their personal trainer.
Study NCT03717363 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational talk
Description: An educational talk given by the nurse and the physiotherapist about the components of a cardiosaluble lifestyle.
Study NCT01723345 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: omega 3
Description: 3 gram omega 3 (400mg EPA and 200mg DHA) 12hours before PCI
Study NCT02230800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocovid SupraBio plus pentoxifylline
Study NCT02230800 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebos
Study NCT03404115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reproxalap Ophthalmic Solution (0.25%)
Description: Reproxalap Ophthalmic Solution (0.25%) administered for approximately twelve weeks.
Study NCT03404115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reproxalap Ophthalmic Solution (0.1%)
Description: Reproxalap Ophthalmic Solution (0.1%) administered for approximately twelve weeks.
Study NCT03404115 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Ophthalmic Solution
Description: Vehicle Ophthalmic Solution administered for approximately twelve weeks.
Study NCT01015209 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Chitosan- N- Acetylcysteine eye drops
Description: Cohort 1: 1 drop once Cohort 2: 2 drops daily for 5 days
Study NCT00129428 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: UVB Irradiation
Description: A dose of up to 320 mJ/cm2 from a UVB irradiation device will be administered at maximum 5 times per week for 16 weeks.
Study NCT04118829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perampanel
Description: For group 1 the PER dose will be administered 2-14 hours prior to sample collection. They will be administered a single dose of PER (8 mg, 12 mg or 16 mg) followed by 4 mg/day for 14 days starting on postoperative day 1 (if continued prophylaxis with PER is needed).~It is anticipated that patients in group 2 will have the daily dose of PER in these individuals will range from 4 - 12 mg/day.
Study NCT03201640 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: slideshow
Description: Participants will be shown a slideshow showing a child being prepared for surgery
Study NCT03201640 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: virtual
Description: Participants will be shown an immersive virtual reality preparation for surgery
Study NCT03578250 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Robotic Training
Description: Upper extremity training on a robotic device with or without error augmentation force field.
Study NCT03680885 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine gel
Description: Lidocaine gel 5%, PEG with FD\&C Blue No.1 (Brilliant Blue FCF)
Study NCT03680885 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: PEG with FD\&C Blue No.1 (Brilliant Blue FCF)
Study NCT03680885 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Injected lidocaine
Description: Standard FDA-approved dental injectable lidocaine
Study NCT02539186 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: platelet rich plasma
Description: Sono-guided injection with 3cc platelet rich plasma between carpal tunnel and median nerve
Study NCT02539186 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: splint
Study NCT00952705 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Q/LAIV-BFS (MEDI8662)
Description: A single dose of Q/LAIV-BFS delivered using the BFS delivery system (0.2 mL) on Day 0.
Study NCT00952705 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: FluMist/B/Yamagata
Description: FluMist/B/Yamagata - 0.2 mL dose at Day 0
Study NCT00952705 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: FluMist/B/Victoria
Description: FluMist/B/Victoria - 0.2 mL dose at Day 0
Study NCT01106989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heated lidocaine/tetracaine patch
Description: Patients will be instructed to apply one heated lidocaine 70 mg and tetracaine 70 mg topical patch directly to each trigger point identified at the Screening/Baseline Visit (up to 3 trigger points). Patches will be administered for 4 hours, 2 times per day (total of 8 hours for each trigger point per day).
Study NCT03344341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Starting dose of dapagliflozin is 5 mg once daily, taken orally in the morning, before or after breakfast. From the third week,the dose can be increased to 10 mg once daily, and last to the end of the study.
Study NCT03344341 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acarbose
Description: Acarbose was started from 50 mg once a day at dinner during the first week and titrated up to 50 mg twice a day at lunch and dinner in the second week, 50 mg three times a day at three meals in the third week, and 100 mg three times a day till the end of the study.
Study NCT03835078 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: methafilcon A contact lenses
Description: Bilateral daily wear of methafilcon A contact lenses
Study NCT03835078 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fanfilcon A contact lenses
Description: Bilateral daily wear of fanfilcon A contact lenses
Study NCT02684968 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colorectal surgery
Study NCT02684968 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Colorectal surgery
Study NCT01155557 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Specific Strength Training
Description: 10 weeks of progressive specific strength training for neck and shoulder muscles.
Study NCT01155557 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle Counseling
Description: 10 weeks of counseling by nurse and physiotherapist in lifestyle changes.
Study NCT02532088 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Oil Palm Phenolics
Description: Palm fruit derived phenolics compound
Study NCT02532088 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03089060 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Silicone Finger cap
Description: Treatment with silicone finger cap
Study NCT03089060 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Silicone Finger cap
Description: Treatment with silicone finger cap
Study NCT03089060 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Film Dressing
Description: Treatment with conventional film dressing
Study NCT03089060 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Film Dressing
Description: Treatment with conventional film dressing
Study NCT02986074 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Paresthesia mapping lead evaluation first
Description: Subjects will evaluate the clinical efficacy of stimulation delivered using the lead implanted using paresthesia mapping in the first part of the SCS trial and using the lead implanted using anatomical midline placement in the second part of the SCS trial
Study NCT02986074 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anatomical midline lead evaluation first
Description: Subjects will evaluate the clinical efficacy of stimulation delivered using the lead implanted using anatomical midline in the first part of the SCS trial and using the lead implanted using paresthesia mapping placement in the second part of the SCS trial
Study NCT00641693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: 16mg Nasal Spray
Study NCT00641693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: 32mg Nasal Spray
Study NCT00641693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: 64mg Nasal Spray
Study NCT00641693 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00660803 — intervention group
Intervention type: DRUG
Intervention: Fulvestrant
Study NCT01055145 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levofloxacin, moxifloxacin
Description: Levofloxacin 750mg po per day for 3 months vs. Moxifloxacin 400mg po per day for 3 months
Study NCT03187509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Torsemide
Description: These subjects who are randomized to a weight-based torsemide regimen will be instructed via phone encounters three times per week to take an individualized dose of torsemide based on their current weight and symptoms. These subjects will have a follow-up study appointment at week 5 for a final weight and blood work to assess kidney function, electrolytes and brain-natriuretic peptide levels.